male factor or for idiopathic infertility., Patients admitted to an IVF/ICSI cycle will be included. The patient will be addresses to the IVF cycles for the following reasons: tubal factor
Conditions
Brief summary
The primary endpoint of the study will be to confirm that the pre-treatment with rhLH at the dose of 187.5 IU/day for 60 days may improve ovarian reserve as indicated by an increase in basal AMH.
Detailed description
• Change of AFC after 30/60 days • Change of AMH after 30 days • Ovarian response • Evaluate the safety of rLH • cycles discontinued/cancelled before rhCG administration • percent of missed transfer of fresh embryos • implantation rate • biochemical pregnancy rate • clinical pregnancy rate • early and late OHSS rate • miscarriage rate • preterm birth rate • low birth weight rate • congenital anomalies rate • gestational age at delivery • mean neonatal weight
Interventions
DRUGLuveris 75 IU powder and solvent for solution for injection
Sponsors
Azienda Ospedaliero Universitaria Di Modena
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of the study will be to confirm that the pre-treatment with rhLH at the dose of 187.5 IU/day for 60 days may improve ovarian reserve as indicated by an increase in basal AMH. | — |
Secondary
| Measure | Time frame |
|---|---|
| • Change of AFC after 30/60 days • Change of AMH after 30 days • Ovarian response • Evaluate the safety of rLH • cycles discontinued/cancelled before rhCG administration • percent of missed transfer of fresh embryos • implantation rate • biochemical pregnancy rate • clinical pregnancy rate • early and late OHSS rate • miscarriage rate • preterm birth rate • low birth weight rate • congenital anomalies rate • gestational age at delivery • mean neonatal weight | — |
Countries
Italy
Outcome results
None listed